Analysts Set ProQR Therapeutics (NASDAQ:PRQR) PT at $8.75

Shares of ProQR Therapeutics (NASDAQ:PRQR) have earned an average recommendation of “Buy” from the eight analysts that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $8.00.

A number of research analysts have issued reports on the stock. HC Wainwright increased their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, March 14th. Oppenheimer decreased their target price on shares of ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Friday, March 14th. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Monday, March 10th. Finally, Cantor Fitzgerald assumed coverage on shares of ProQR Therapeutics in a research report on Tuesday, April 29th. They set an “overweight” rating and a $8.00 price target on the stock.

Institutional Trading of ProQR Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $30,000. Invesco Ltd. acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $32,000. Alpine Global Management LLC acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $39,000. Two Sigma Securities LLC acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $40,000. Finally, ADAR1 Capital Management LLC acquired a new stake in ProQR Therapeutics in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Stock Down 0.6%

ProQR Therapeutics stock opened at $1.62 on Friday. The stock has a market cap of $170.45 million, a P/E ratio of -5.06 and a beta of 0.35. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.62. The company’s 50-day moving average price is $1.46 and its two-hundred day moving average price is $2.33.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $4.90 million. Equities analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).